M&A Analysis: 2019 Promises Buoyant Year For M&A
Executive Summary
After a record year for medtech M&A deal-making in 2018, Medtech Insight investigates how activity may unfold in the coming year and some of the biggest trends that could hit the industry.
You may also be interested in...
Boston Scientific Agrees To Pay $4.2Bn For UK Interventional Oncology Firm BTG
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
Medtronic Buys Mazor Robotics For $1.3Bn
Medtronic is straightening up as a market leader in spinal surgery after agreeing to buy the shares of Mazor Robotics that it does not already own. The $1.3bn deal builds on an existing agreement between the companies formed in May 2016 and strengthens Medtronic as the front runner in the spine robotics field.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.